Taylor & Francis

While at the AAN Annual Meeting (Boston, MA, USA, 22–28 April 2017), we spoke with Dr Michael Alosco, a fellow at Boston University Alzheimer’s Disease and CTE Center(MA, USA), who is currently working on multiple projects looking at chronic traumatic encephalopthy (CTE)in both living and deceased patients. Michael discussed his work, progress towards diagnosis of CTE in life and his thoughts on the latest in CTE research.

You can find more NCTalks podcasts, as well as the latest news, journal articles and interviews with experts across neuroscience and neurology at www.neuro-central.com

Reporting from ECCMID17, we spoke to William Irving about his current work on hepatitis C and his thoughts on the future of this field.

Whilst at the American Academy of Neurology’s Annual Meeting (Boston, MA, USA, 22–28 April 2017), we sat down with Michael Pender (University of Queensland, Australia), who was presenting promising interim findings from a Phase 1 study investigating a novel treatment for multiple sclerosis (MS) at the meeting.

In this interview, Dr Pender discusses the relationship between MS and the Epstain-Barr virus; a link that has been observed in recent studies, and which forms the basis of this most recent clinical trial. In the Phase I study, researchers removed the T cells from six patients with progressive MS, stimulated the T cells to increase their ability to recognize and destroy Epstein-Barr virus-infected B cells, and the injected these T cells in infusions every 2 weeks over a 6-week period. At this interim point, three participants have showed improvement, with one showing “striking improvement”. In the interview, Dr Pender, lead researcher of the trial, discusses the key findings of the trial, and the next steps following these exciting developments.

You can find more AAN coverage, as well as podcasts on a range of topics across neurology and neuroscience, here: www.neuro-central.com

In this interview, Joop Arends discusses his thoughts on the future of diagnosis and management of hepatitis C, and also gives us his highlights from ECCMID.

In this interview, Greg Roman (Waters Corporation, USA) shares his experience with instrumentation and techniques such as LC–MS and HRMS and explains what drew him to the field.

In this edition of NCTalks, Lauren Pulling speaks to Emery Brown, Professor of Anesthesia at Harvard Medical School (MA, USA). Dr Brown has delivered a number of lectures in recent years on deciphering the dynamics of the brain under general anaesthesia, and how the potential of this area may currently be under-utilized. In this podcast we’ll hear more about Dr Brown’s work, how general anesthesia can be used to understand and develop new treatments for neurological and psychiatric conditions, and we’ll look ahead at the future of the field.

In this EpigenomicsNet podcast, Professor Hendrik Stunnenberg (Radboud University, Nijmegen, Netherlands) discusses his work in gene expression, investigating regulatory epigenetic mechanisms and provides a summary of his talk on the epigenome of innate immune cells.

In this EpigenomicsNet podcast, Dr En Li (Novartis Institutes for BioMedical Research, Shanghai, China) discusses his work leading Novartis’ research program in Shanghai and provides a summary of his talk on Novartis’ epigenetic research in cancer.

In this EpigenomicsNet podcast, Dr Danette Daniels (Promega, Madison, WI, USA) discusses her work at Promega in the area of functional proteomics and provides a summary of her talk introducing Promega’s technologies to study and characterize protein interactions inside cells, particularly for chromatin analysis.

In this MedChemNet podcast, Professor Paul Fish (University College London, UK) discusses his work in Alzheimer’s drug discovery and the talk he delivered on the discovery of fit for purpose chemical probes to investigate bromodomain proteins and the three new drug discovery institutes funded by Alzheimer’s research UK.